Form 8-K · Current report
Amgen 8-K, filed Aug 4, 2026
- Filed
- CIK
- 0000318154
- Accession no.
- 0000318154-26-000124
Summary
Amgen reported second-quarter 2026 total revenues of $10.1 billion, up 10% year over year, with GAAP earnings per share of $4.37 versus $2.65 a year earlier and non-GAAP earnings per share of $6.29 versus $6.02. Chairman and chief executive Robert A. Bradway said the company's six key growth drivers grew 26% year over year and generated nearly 70% of second-quarter product sales.
Key points
- Second-quarter product sales rose 9% on volume growth, with 22 products posting at least double-digit sales growth and 17 annualizing above $1 billion.
- Repatha sales rose 37% to $953 million and EVENITY 38% to $714 million, while Prolia fell 32% to $759 million as multiple biosimilars launched globally.
- Free cash flow was $3.5 billion, up from $1.9 billion in the second quarter of 2025.
- Enbrel sales fell 4% to $580 million, which Amgen attributed in part to U.S. Medicare Part D price setting under the Inflation Reduction Act effective January 1, 2026, and a larger 340B Program mix.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. Second Quarter 2026 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On August 4, 2026, the Company issued a press release announcing its unaudited results of operations for the three and six months ended June 30, 2026, and its unaudited financial position as of June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Generally Accepted Accounting Principles (GAAP) financial measures as defined in Regulation G promulgated by the Securities and Exchange Commission. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.